Zoom link => https://us02web.zoom.us/j/87417667754
Generation of novel therapeutics for neuromuscular diseases through collaboration with disease and target biology academic experts and argenx antibody expertise
Carol Walton and René Bigirimana
Carol Walton, Director of Business Development at argenx and René Bigirimana, Scenior scientist at argenx
Argenx strives to combine its technical antibody expertise with external expertise on biological targets through collaborations. Within our Immunology Innovation Program (IIP), we aim to generate novel therapeutic approaches for high unmet need peripheral neuromuscular indication by collaborating with external scientific and academic experts to gain novel insights in disease and target biology. argenx will provide an Introduction to its Immunology Innovation Program for collaboration with some of our illustrative collaboration on C2 antibody ARGX 117 for MMN and Musk agonist antibody ARGX-119.